Current nosology of Treatment Resistant Depression: A controversy resistant to revision

Clinical Practice and Epidemiology in Mental Health

Volumn 6, Issue , 2010, Pages 20-24

  Fornaro, Michele ^a   Giosuè, Patricia ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b National Health Trust   (Italy)

Author keywords

Bipolar Disorder; Controversy; Treatment Resistant Depression

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUOXETINE; HERBACEOUS AGENT; INOSITOL; LAMOTRIGINE; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; OMEGA 3 FATTY ACID; PINDOLOL; PLACEBO; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BIPOLAR DEPRESSION; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; PREVALENCE; REMISSION; REVIEW; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; THERAPY RESISTANCE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79960602647     PISSN: None     EISSN: 17450179     Source Type: Journal    
DOI: 10.2174/17450179010060100020     Document Type: Review

References (55)

1. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress Anxiety 2008; 25(12): 989-92.
2. Little A. Treatment-resistant depression. Am Fam Physician 2009; 80(2): 167-72.
3. WHO. The World Health Report 2001 - Mental Health: New Understanding, New Hope. World Health Organization. Geneva: World Health Organization; 2001.
4. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354(12): 1243-52.
5. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing withinversus across-class switches. Biol Psychiatry 2008; 63(7): 699-704. (Pubitemid 351329277)
6. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005; 25(4): 336-41. (Pubitemid 41060253)
7. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004; 164(11): 1197-204. (Pubitemid 39030356)
8. Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004; 56(1): 46-53. (Pubitemid 38813405)
9. *D: implications for clinical practice. Am J Psychiatry 2006; 163(1): 28-40. (Pubitemid 43050100)
10. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19(1): 34-40.
11. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58(5): 347-54. (Pubitemid 41219702)
12. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006; 67(11): 1754-9. (Pubitemid 44955157)
13. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60(4): 221-5. (Pubitemid 29193918)
14. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004; 24(5): 507-11. (Pubitemid 39274204)
15. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25(6): 1171-80.
16. Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis 2003; 191(7): 444-9. (Pubitemid 36944625)
17. Snaith RP. Hamilton rating scale for depression. Br J Psychiatry 1977; 131: 431-2.
18. Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand 2005; 112(4): 302-9. (Pubitemid 41382737)
19. Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 2001; 62(4): 221-4. (Pubitemid 32428758)
20. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006; 67 (Suppl 6): 16-22. (Pubitemid 44078108)
21. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 1990; 26(4): 429-60.
22. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry 2001; 62 (Suppl 18): 18-24. (Pubitemid 33736201)
23. Thase ME. Management of patients with treatment-resistant depression. J Clin Psychiatry 2008; 69(3): e8.
24. Schmauss M, Messer T. Treatment-Resistant Depression. Fortschr Neurol Psychiatr 2010; 78(3): 169-83.
25. Posternak MA, Zimmerman M. How accurate are patients in reporting their antidepressant treatment history? J Affect Disord 2003; 75(2): 115-24. (Pubitemid 36645244)
26. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther 2009 [Epub ahead of print].
27. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999; 52(1-3): 135-44. (Pubitemid 29232042)
28. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52(1): 46-54. (Pubitemid 46743497)
29. APA, Ed. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR). Washington, D.C. 2000.
30. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58 (Suppl 13): 23-9. (Pubitemid 28011969)
31. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9(1-2): 83-91. (Pubitemid 29073687)
32. Bannan N. Multimodal therapy of treatment resistant depression: a study and analysis. Int J Psychiatry Med 2005; 35(1): 27-39. (Pubitemid 41056526)
33. Swann AC. The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci 2010; 1187: 276-93.
34. Hamann S. Blue genes: wiring the brain for depression. Nat Neurosci 2005; 8(6): 701-3. (Pubitemid 43085830)
35. Giacobbe P, Mayberg HS, Lozano AM. Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. Exp Neurol 2009; 219(1): 44-52.
36. Fountoulakis KN, Gonda X, Rihmer Z, Fokas C, Iacovides A. Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study. Ann Gen Psychiatry 2008; 7: 22.
37. Elliott RL. Depression in primary care. Ethn Dis 2007; 17 (Suppl 2): S2-28-33.
38. Fraguas R Jr., Henriques SG Jr., De Lucia MS, et al. The detection of depression in medical setting: a study with PRIME-MD. J Affect Disord 2006; 91(1): 11-7. (Pubitemid 43254632)
39. *D study: implications for clinicians and drug developers. J Psychiatr Pract 2009; 15(1): 45-9.
40. *D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv 2008; 46(10): 21-4.
41. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003; 5 (Suppl 2): 36-47. (Pubitemid 38444336)
42. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68(6): 935-40. (Pubitemid 47015495)
43. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166(9): 980-91.
44. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res 1998; 79(2): 163-73. (Pubitemid 28308489)
45. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73(3): 159-71. (Pubitemid 28088172)
46. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J Affect Disord 2005; 84(2-3): 251-7. (Pubitemid 40222507)
47. Faravelli C, Gorini Amedei S, Scarpato MA, Faravelli L. Bipolar Disorder: an impossible diagnosis. Clin Pract Epidemol Ment Health 2009; 5: 13.
48. Sharma V. Treatment resistance in unipolar depression: Is it an iatrogenic phenomenon caused by antidepressant treatment of patients with a bipolar diathesis? Med Hypotheses 2006; 67(5): 1142-5. (Pubitemid 44314154)
49. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 2005; 85(1-2): 3-16. (Pubitemid 40386521)
50. Hantouche EG, Akiskal HS, Lancrenon S, Chatenet-Duchene L. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord 2005; 84(2-3): 243-9. (Pubitemid 40222506)
51. Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005; 88(2): 217-33. (Pubitemid 41266904)
52. Benazzi F. Depressive mixed states: unipolar and bipolar II. Eur Arch Psychiatry Clin Neurosci 2000; 250(5): 249-53.
53. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163(2): 210-6. (Pubitemid 44480839)
54. *D, and the return of neurotic depression. Bipolar Disord 2008;10(8): 957-68.
55. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120(6): 429-40.